Systematix Sec. (531432)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹6.99, this is a tiny ₹4 crore market cap NBFC selling at 0.40 times book value of ₹17.55. On the surface, Graham might call it an asset play. But Buffett would ask: can these assets earn a return? The answer is no. ROE is -0.99%, ROCE is -0.92%, the latest quarter shows zero sales and zero net profit. A company with no revenue and no profit is not an operating business; it is a shell. The Piotroski F-score of 2/9 reinforces weak fundamentals. There is no dividend, no growth, and no promoter holding disclosed. The price is even below the stated 52-week range of ₹9.35-₹18.95, which is unusual; either the data is stale or the market is repricing distress. Debt-to-equity is not available, so I cannot judge solvency. For an NBFC, asset quality is everything, but with zero revenue I cannot see any loan book or interest income. The margin of safety from book value is meaningful only if that book value is trustworthy and realisable. A liquidation or capital return could unlock value, but there is no evidence management intends to do that. I would not call this a grower or a stalwart. It is a possible asset play, for a patient investor willing to read annual reports, verify net worth, and understand why the market values it at only 40% of stated book. If the assets are good and operations restart, the upside could be significant. But with negative returns and no revenue, the default path is value destruction. I would keep any position small and speculative, and only after independent verification. Price is not always value; sometimes a discount is merely a discount to a shrinking net worth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer